Nasal spray vaccine shows promise against common childhood virus
NCT ID NCT01893554
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new nasal spray vaccine for respiratory syncytial virus (RSV), a common cause of serious breathing problems in babies and young children. The vaccine was given as nose drops to 88 healthy children aged 4 months to 5 years, including those who had and had not been infected with RSV before. The goal was to see if the vaccine is safe and helps the body build immunity against RSV.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESPIRATORY SYNCYTIAL VIRUS INFECTIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Center for Immunization Research (CIR)
Baltimore, Maryland, 21205, United States
-
Center for Immunization Research South
Laurel, Maryland, 20708, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Nasal spray vaccine aims to shield children from RSV
- Inhaled interferon could be new weapon against severe RSV in young children
- New oral pill aims to fight RSV in adults
- New antiviral pill aims to shorten RSV symptoms in vulnerable adults
- New rapid test could spot flu and RSV in minutes at your local clinic
- Experimental 'Storm Stopper' therapy tested for COVID-19, flu, and RSV